ArticleWiener klinische Wochenschrift2014
Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis.
Article in Wiener klinische Wochenschrift, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- Evaluation of Serum Prolidase as a Biomarker and the Effects of Nintedanib in an Experimental Rat Model of Silicosis.Journal of clinical medicine · 2026Article
- Evaluation of Thiol Disulfide, Ischemia Modified Albumin, and Prolidase Parameters in Patients with Localized Scleroderma.Dermatology practical & conceptual · 2024Article
- Review
- Sirtuins and Accelerated Aging in Scleroderma.Current rheumatology reports · 2018Review
- Serum prolidase activity in systemic sclerosis.Clinical rheumatology · 2017Article
- Serum prolidase level in ankylosing spondylitis: low serum levels as a new potential gold standard biomarker for disease activity.Rheumatology international · 2016Article
- Oxidative stress and antioxidant strategies in dermatology.Redox report : communications in free radical research · 2016Review
- High proline-related inhibition of serum prolidase enzyme activity in scleroderma.Wiener klinische Wochenschrift · 2016Article
- Prolidase Enzyme Activity in Conjunctiva and Pterygium Tissues.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- Antioxidants of Edible Mushrooms.Molecules (Basel, Switzerland) · 2015Review
- Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor β.Arthritis & rheumatology (Hoboken, N.J.) · 2015Article
- Role of cellular senescence and NOX4-mediated oxidative stress in systemic sclerosis pathogenesis.Current rheumatology reports · 2015Review
Corrections and comments
- Commented on by
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSystemic sclerosis (SSc) is a disease characterized by fibrosis of the skin and organs; it is associated with diffuse fibroproliferative microangiopathy and autoimmune background. The studies have shown that the production of excessive free radicals and increased collagen synthesis by the fibroblasts play an important role in the pathophysiology of SSc. Prolidase is an important marker in collagen turnover. We aimed to compare total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), and prolidase levels of SSc patients and healthy controls. We also investigated the relationship between prolidase and oxidative stress.
methodsA total of 38 SSc patients and 33 healthy volunteers were included in the study. Serum TAS, TOS, and prolidase activity were evaluated in the groups.
resultsIt was found that the TOS and OSI levels of patients were higher than those in the control group (P = 0.012 and 0.015, respectively), whereas TAS was not significantly different between groups (P = 0.451). Prolidase activity was lower in patients than in controls (P = 0.008). There was a weak correlation between prolidase and OSI in patients. It was found that TAS was lower by marginal significance in the patients with lung and gastrointestinal tract (GT) involvement than the patients without those (P = 0.067 and 0.059, respectively).
conclusionsOur data suggest that oxidative stress is increased in SSc. TAS is decreased in patients with lung and GT involvement. These results support that antioxidant treatment may be useful in SSc, especially in patients with lung and GT involvement. Antioxidant treatment may prevent organ involvement in SSc. TAS may be a marker that predicts the risk of involvement of a specific organ. In addition, prolidase may be a marker of SSc.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.